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Abstract: Duloxetine is a relatively balanced serotonin and noradrenaline reuptake inhibitor 
(SNRI), which is the ﬁ  rst drug with widely proven efﬁ  cacy to have been licensed for the medical 
treatment of women with stress urinary incontinence (SUI). Despite favorable results from 
randomized controlled trials, surgical management continues to be the mainstay of treatment 
for SUI. In this review we explore the pharmacology of duloxetine in the nervous system and 
lower urinary tract, and the evidence for its use in the management of women with urinary 
incontinence.
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Introduction
Urinary incontinence is a highly prevalent chronic medical condition which has a known 
negative impact on quality of life in women. It can impact signiﬁ  cantly on physical 
activities, conﬁ  dence and self-perception and social activities.1 There is also a known 
association between lower urinary tract symptoms (LUTS) and female sexual dysfunction.2 
Urinary incontinence may be further categorized as stress urinary incontinence (SUI), 
urge urinary incontinence (UUI) or mixed urinary incontinence (MUI). SUI is deﬁ  ned as 
the complaint of involuntary leakage of urine upon effort or exertion, or on sneezing or 
coughing.3 SUI is estimated to affect 78% of incontinent women with 29% complaining 
of SUI in combination with urge incontinence, and 49% complaining of pure SUI. 
Despite the prevalence of stress urinary incontinence and the signiﬁ  cant impact that 
it can have on all domains of quality of life and personal relationships, it is estimated 
that only a third of women ever seek medical advice concerning their incontinence.4 
Reasons for this reticence are varied and include embarrassment, lack of knowledge of 
available treatment options and the belief that incontinence is an inevitable consequence 
of childbirth or ageing. Unfortunately lack of awareness also exists amongst primary 
care physicians, with management often being based purely on containment products. 
This has considerable economic considerations, with one study estimating pad costs in 
women with incontinence at US$750 per woman per year.5
Management of women with SUI is initially conservative with a period of pelvic ﬂ  oor 
muscle training. Until recently, the next treatment option offered to women with persistent 
symptoms was a surgical procedure to correct the anatomical defect. This is now most 
commonly a suburethral sling, either retropubically or via a transobdurator approach. Long 
term data on the most established suburethral sling (Tension Free Vaginal Tape, TVT) has 
shown it to be a highly effective treatment for stress leakage with success rates of 81% 
at 5 years.6 This treatment escalation from conservative management directly to surgical 
management reveals a distinct gap for effective medical treatments. Medications such as 
estrogens and tricyclic antidepressants have been used off label in the past for SUI with 
little or no evidence of efﬁ  cacy and often signiﬁ  cant side effects. The introduction of the 
serotonin and noradrenaline reuptake inhibitor (SNRI) duloxetine as a drug therapy for Clinical Interventions in Aging 2009:4 26
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stress incontinence was hailed as a signiﬁ  cant step forward in 
terms of widening treatment options for women with SUI. It 
was the ﬁ  rst available pharmacological option for SUI which 
had proven efﬁ  cacy in randomized controlled trials, thus 
ﬁ  lling the treatment void between conservative and surgical 
therapies. In this article, we discuss the mechanism of action 
of duloxetine in the lower urinary tract and central nervous 
system, the original uses of duloxetine in psychiatric disorders 
and chronic pain, and the available evidence regarding the use 
of duloxetine in women with incontinence.
Duloxetine in the management 
of depression and pain
Duloxetine was originally developed for use in patients with 
major depressive disorder and more recently, chronic pain. It has 
been shown in a number of studies that there is a considerable 
overlap of both incontinence and chronic pain symptoms in 
subjects with depression.7 It was only once the wide-ranging 
roles of serotonin and noradrenaline in the central and peripheral 
nervous systems were understood that a common neuro-
biochemical etiology could be appreciated, and the dual efﬁ  cacy 
of duloxetine in depression and pain plus incontinence could be 
explained. High concentrations of serotonin and noradrenaline 
terminals are found in the spinal cord, particularly the superﬁ  cial 
dorsal/posterior horns. Serotonin and noradrenaline have been 
shown to be critical to the modulation of pain perception via their 
effects on inhibitory pain pathways.8 The pathophysiology of 
persistent pain is poorly understood, however there is increasing 
evidence that imbalance of noradrenaline and serotonin based 
pathways may play a major role.9 Noradrenaline and serotonin 
terminals are also widespread in higher brain centers responsible 
for regulation of emotions and mood, particularly the limbic 
system. A deﬁ  ciency in one or more monoamine neurotransmit-
ters can lead to the development of anxiety and clinical depres-
sion.10 This is the basis for the use of SNRIs such as duloxetine 
in patients with clinical depression. Duloxetine is thought to 
increase the availability of serotonin and noradrenaline in the 
synaptic cleft in centers involved in the regulation of mood and 
emotions. It has been shown to be a safe and effective treatment 
in several randomized controlled trials.11–13 Similarly, duloxetine 
has been the subject of study as a treatment for chronic pain due 
to diabetic peripheral neuropathy and has had its efﬁ  cacy and 
safety proven in further randomized controlled trials.14
Effect of duloxetine on the lower 
urinary tract
SUI is thought to arise either due to poor functioning of the 
striated muscle of the urethral sphincter (instinsic sphincter 
deﬁ  ciency, ISD)15 or urethral hypermobility due to loss of 
vaginal support structures.16 It is increasingly believed that 
both may co-exist to some degree in the majority of women 
with SUI. Although interventions such as suburethral slings 
correct the hypermobility of the urethra, duloxetine is thought 
to act on the sphincter muscle itself.
The neurological control of the lower urinary tract has 
been elegantly studied in animal models, giving us insight 
into the role of neurotransmitters, both centrally and 
peripherally. The micturition cycle consists of a storage 
phase and a voiding phase. During the storage phase, the 
detrusor muscle relaxes to accommodate urine, whilst 
the outlet resistance is enhanced via increased tone of the 
rhabdosphincter, pelvic ﬂ  oor and urethral smooth muscle. 
This mechanism is thought to be mediated by cholinergic 
mechanisms. It has been demonstrated in animal and human 
studies that the pelvic ﬂ  oor has a nerve supply from branches 
of the levator ani nerve (from sacral nerve roots S3–S5).17,18 
One may assume that activity of these nerves causes pelvic 
floor contraction. The overall process is co-ordinated 
by the central nervous system with glutamate being the 
main neurotransmitter for the storage phase. Glutamate is 
released to Onuf’s nucleus (in the ventral horn of the sacral 
spinal cord), which activates the pudendal nerve, causing 
a release of acetylcholine and eliciting contraction of the 
rhabdosphincter.19 Both noradrenaline and serotonin are 
thought to have a modulatory effect on rhabdosphincter 
contraction, with enhanced activity of the sphincter ﬁ  bres 
in their presence. Onuf’s nucleus is known to be densely 
populated with serotonin and noradrenaline receptors 
and terminals which further implies an important role for 
these neurotransmitters in the control of the lower urinary 
tract. It should be noted however that noradrenaline and 
serotonin are unable to induce rhabdosphincter contraction 
in the absence of glutamate,20 implying that glutamate is 
the ultimate controller of motor activity, with serotonin and 
noradrenaline merely potentiating its effects. During the 
voiding phase of the micturition cycle, glutamate release 
to Onuf’s nucleus ceases, leading to cessation of pudendal 
nerve activity. Again, this is independent of serotonin and 
noradrenaline.
The effects of duloxetine are thought to be mediated by 
an increase in the availability of serotonin and noradrenaline 
in the synaptic clefts of Onuf’s nucleus.
This was ﬁ  rst studied by Thor and colleagues in a cat 
model of bladder irritation.21 Administration of duloxetine 
lead to a dose dependent increase in bladder capacity and 
enhanced periurethral striated muscle activity. Duloxetine did Clinical Interventions in Aging 2009:4 27
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not affect bladder contractions caused by direct electrical 
stimulation of efferent ﬁ  bres in the pelvic nerve, leading to 
the supposition that its effects are due to central rather than 
peripheral mechanisms. These early studies in animals lead to 
mechanistic studies in human subjects. Boy et al demonstrated 
a lower motor threshold for sphincter contraction in response 
to cortical stimulation and increased pressure amplitudes 
in response to sacral magnetic stimulation, supporting 
the conclusion that duloxetine facilitates a positive 
neuromodulatory effect on the urethral sphincter.22 Another 
study of duloxetine versus placebo in women with SUI showed 
a trend towards an increase in Valsalva leak point pressure 
and urethral pressure proﬁ  le parameters in women taking 
duloxetine.23 A study of the effect of duloxetine on urethral 
pressure and sphincter morphology showed significant 
increases in mean urethral retro-resistance pressure, maximum 
urethral closure pressure and sphincter width after 8 weeks’ 
treatment with duloxetine.24 A sub-analysis of women who 
had a symptomatic improvement with duloxetine revealed 
these increases to be even more marked. Another ultrasound 
study has conﬁ  rmed that duloxetine leads to a signiﬁ  cant 
increase in the width of the smooth muscle component of 
the urethral sphincter, with no corresponding increase in 
urethral length,25 which raises the interesting prospect that 
duloxetine leads to enhanced activity of smooth as well as 
striated muscle. The available evidence would seem to support 
the conclusion that duloxetine improves the symptom of SUI 
by increasing urethral closure pressure and potentiating the 
electrical activity of the sphincter.
Management of SUI with duloxetine
These early studies have been supported by several large 
phase 2 and 3 trials, which aimed to more clearly delineate 
the efﬁ  cacy and safety of duloxetine in women with SUI. 
One of the ﬁ  rst was a double blind randomized placebo 
controlled study in which 553 women with SUI received 
placebo, 20 mg duloxetine, 40 mg duloxetine or 80 mg 
duloxetine for 12 weeks.26 The authors reported signiﬁ  cant, 
dose dependent improvements in quality of life and incon-
tinence episode frequency (IEF) and an increase in average 
voiding interval in women taking duloxetine. There was a 
high placebo response, with a 41% decrease in IEF in the 
placebo group (compared to a 54% decrease in the duloxetine 
20 mg group). Similar results were seen in a subgroup of 
women with severe SUI. Discontinuation rates for adverse 
events were 9, 12 and 15% in the 20, 40 and 80 mg groups 
respectively, versus 5% in the placebo group. The most 
common adverse event was nausea.
Duloxetine was further evaluated in several phase 3 trials. 
A 2003 trial which randomized 683 North American women 
to placebo, 80 mg duloxetine once daily or 40 mg duloxetine 
twice daily over a 12 week period showed duloxetine to cause 
a signiﬁ  cant decrease in median IEF (57% vs 27%, p   0.001) 
and a signiﬁ  cant improvement in quality of life scores 
(11.0 vs 6.8, p   0.001).27 This study also addressed the 
question of whether the beneﬁ  ts experienced by women on 
duloxetine may be due to treatment of underlying depressive 
symptoms, by using a validated depression inventory as 
an outcome measure; this demonstrated no significant 
change in depressive symptoms after treatment with either 
duloxetine or placebo. 24% of women in the duloxetine 
group discontinued the medication, most commonly due 
to nausea. These ﬁ  ndings were subsequently conﬁ  rmed in 
another phase 3 trial involving 494 European and Canadian 
women, which again showed a signiﬁ  cant decrease in median 
IEF for women taking duloxetine versus placebo (50% vs 
29%, p = 0.002).28 Again, nausea was experienced by 27.9% 
of the treatment group (vs 6.5% in the placebo group, 
p   0.001), although 83% of the patients who developed 
nausea whilst on duloxetine did complete the study. A third 
phase 3 trial of women across 4 continents found similar 
results,29 although with a higher placebo response (40%) than 
in the previous phase 3 studies. The authors attribute this to 
a possibly higher number of treatment naïve subjects in this 
trial, owing to the diverse geographical regions in which 
patients were recruited.
Overall, these 3 parallel phase 3 studies randomized 
1635 women with SUI worldwide to receive duloxetine in var-
ious doses or placebo. Each study consistently showed dulox-
etine to lead to appreciable decreases in IEF (50%–54%) with 
improvements in quality of life and signiﬁ  cant increases in 
voiding intervals, indicating that the reduction in incontinence 
episodes was not merely due to learned behaviour developed 
over the course of the trials. These results were reinforced by 
a trial which showed duloxetine to be more effective than pel-
vic ﬂ  oor muscle training or no treatment, and that duloxetine 
and pelvic ﬂ  oor muscle training had an additive effect when 
used together.30 This presumably reﬂ  ects the complementary 
modes of action of these therapies.
Based on the assumption that the mode of action of 
duloxetine involves enhanced activity of the rhadbosphincter, 
there have been concerns that it may be less efﬁ  cacious 
in older women due to age-related changes in the striated 
portion of the urethral sphincter.31 Older patients may also 
be more prone to developing adverse effects as a result of 
drug therapy. A pooled data analysis of 4 large randomized Clinical Interventions in Aging 2009:4 28
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controlled trials showed women over 65 to have a slightly 
diminished reduction in IEF, although response differences 
when compared to placebo were still maintained.32 Indeed, 
in an analysis of factors that may have been likely to reduce 
patient response to duloxetine (such as age, body mass index, 
hypo-estrogenism), the only identiﬁ  able factor in this paper 
which predicted a lack of treatment response was chronic 
lung disease. The issue of age has been studied more directly 
by Schagen van Leeuwen and colleagues.33 In a 12-week 
randomized double blind trial of duloxetine versus placebo 
in women with SUI or stress predominant mixed UI over 
the age of 65, signiﬁ  cant reductions in IEF with duloxetine 
were seen; the response rate was comparable to that in the 
phase 3 studies. There was no signiﬁ  cant difference in 
discontinuation rates between the treatment groups, and 
interestingly the incidence of nausea was not signiﬁ  cantly 
higher in the duloxetine group. The most common adverse 
effects in this cohort were dry mouth, fatigue, constipation 
and hyperhidrosis.
These encouraging trial results seem to suggest that 
duloxetine is a viable and efﬁ  cacious alternative to surgery. 
However, there are common limiting factors with each 
of the trials discussed, which makes it difﬁ  cult to assess 
whether the results can be applied to a “real world” situation. 
Placebo responses of up to 40% were seen in the initial trials 
of duloxetine.26–29 Although the decreases in IEF seen with 
duloxetine were found to be signiﬁ  cantly different from 
those occurring with placebo, this does raise the issue of 
whether the reported symptom improvement in these trials 
was partially attributable to the non-pharmacological beneﬁ  ts 
that being in a trial confers, for example regular contact with 
physicians and continence advisors. In addition, the study 
period for each of the phase 3 trials was limited to 12 weeks. 
It could be argued that this does not reﬂ  ect use of duloxetine 
outside of a trial situation since women may be more willing 
to tolerate adverse effects, as they know the time over which 
they will have to take the medication is limited.
This has been addressed in two papers reporting out-
comes in a cohort of women prescribed duloxetine in routine 
clinical practice, outside of a trial environment. The cohort 
consisted of 228 women with urodynamic stress incontinence 
who were prescribed duloxetine as an alternative to surgery. 
67% of the cohort were started on 40 mg duloxetine twice 
daily, and remained on this dose for the initial 4-week study 
period. 33% were treated with an escalating dose (20 mg 
twice daily, increasing the 40 mg twice daily after 2 weeks. 
68% of patients discontinued duloxetine within the ﬁ  rst 
4 weeks of treatment, mainly because of adverse effects. 
Discontinuation due to adverse effects was more common 
in women who were started immediately on the 40 mg 
twice daily dose compared with the escalating dose. In 
women who were able to tolerate duloxetine, 67% reported 
an improvement in their symptoms, although the overall 
improvement rate was just 37%.34 It is immediately obvious 
that the discontinuation rates and overall efﬁ  cacy reported 
in this paper are inferior to those found in the pooled 
phase 3 studies, leading the authors to conclude that the 
tolerability of duloxetine in a non-trial situation is poorer than 
one might expect. This initial paper focussed on outcomes 
after four weeks’ treatment, since 100% response has been 
seen by day 15 of treatment in previous studies.35 Outcomes 
for the same cohort one year after commencing duloxetine 
therapy have more recently been reported.36 At this point, 
just 9% of the cohort continued to take duloxetine, with 82% 
having undergone a tension free vaginal tape. Of the women 
who discontinued duloxetine, 33% did so because of lack of 
efﬁ  cacy, 56% because of side effects and 11% because of 
an unwillingness to take long term medication.
Management of overactive bladder 
with duloxetine
The early animal studies of the actions of duloxetine on 
the lower urinary tract indicated that as well as leading to 
enhanced periurethral striated muscle activity, it also caused 
a dose dependent increase in bladder capacity.21 This raises 
the question of whether it has any treatment effects in women 
with overactive bladder syndrome (OAB) and/or detrusor 
overactivity (DO). A recently published study comparing 
duloxetine to placebo in women with OAB symptoms 
with or without DO, but excluding those with urodynamic 
evidence of stress incontinence showed duloxetine treatment 
to cause a signiﬁ  cant reduction in voiding episodes and 
urge incontinence episodes, when compared to placebo.37 
There were also observable increases in voiding intervals. 
A further study examined the effect of duloxetine in women 
with mixed incontinence (MUI), with the classiﬁ  cation of 
the incontinence (for example, urge predominant mixed 
incontinence) carried out based on either patient reported 
symptoms using a validated questionnaire or urodynamic 
studies. The authors found that duloxetine reduced both stress 
incontinence episodes and urge incontinence episodes38 in 
women with stress predominant MUI and urge predominant 
MUI respectively. It is interesting to note in this trial that 
these same beneﬁ  ts were not seen in women with balanced 
MUI; the authors attribute this to the small numbers of 
women within this group. These studies and others would Clinical Interventions in Aging 2009:4 29
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seem to indicate that the role of serotonin and noradrenaline 
in control of the lower urinary tract is more widespread than 
ﬁ  rst thought. Certainly they support the hypothesis that 
SNRIs may provide an alternative therapeutic approach 
to OAB symptoms; however direct comparative studies of 
SNRIs and the current standard antimuscarinic treatments 
would need to be carried out before any ﬁ  rm conclusions 
can be drawn.
Investigations of other SNRIs 
in the management of SUI
Following on from the sizeable amount of evidence 
concerning the use of duloxetine in women with SUI, there 
has been interest in exploring other SNRIs, which may have 
a more favorable side effect proﬁ  le. The only drug to be 
studied in any detail so far is venlafaxine, which is another 
anti-depressant drug. It is used elsewhere in gynecological 
practice for the management of hot ﬂ  ushes. Animal studies 
have shown venlafaxine to lead to a signiﬁ  cant increase 
in urethral pressure proﬁ  le parameters,39 which makes it a 
plausible alternative to duloxetine. This has been explored 
in a recent small randomized control trial which compared 
outcomes in 20 women taking venlafaxine to 20 women 
taking placebo.40 The authors report signiﬁ  cant decreases 
in IEF and increases in quality of life in women with SUI 
taking venlafaxine. 40% of women in the active treatment 
group complained of nausea, however none discontinued the 
trial because of this. Interestingly, there was no signiﬁ  cant 
placebo effect seen in this trial in terms of IEF, quality of 
life measures, or patient global impression of improvement. 
The reasons for this are unclear since the trial design and 
frequency of follow up for this trial were similar to that 
of the duloxetine phase 2 and 3 trials. Possibly the smaller 
number of participants in this trial is implicated in this. Futher 
studies of venlafaxine (including head to head studies with 
duloxetine) are necessary to determine whether it may be a 
preferable drug to duloxetine for women with SUI.
Overall role of duloxetine
The overall place for medical agents such as duloxetine in the 
management of women with SUI remains unclear. Certainly, 
clinical guidelines seem to favor surgery over duloxetine, 
possibly because it is more cost effective.41 There is a wealth 
of good quality evidence from randomized controlled trials 
supporting signiﬁ  cant treatment beneﬁ  ts in women taking 
duloxetine when compared to placebo.26–29 However, this is 
complicated by a relatively high incidence of adverse effects, 
most commonly nausea. The studies of duloxetine in a non-trial 
situation indicate that women are seemingly less willing to put 
up with adverse effects, leading to a high discontinuation 
rate. Other randomized studies have overcome this by dose 
escalation regimes, but again, this has been in the context of 
a clinical trial for a ﬁ  nite treatment period.42 The majority of 
women may eventually opt for surgical treatment in the form 
of a TVT or other sub-urethral sling. The trend towards less 
invasive surgical options in urogynecology certainly makes 
surgical treatment a less radical and risky option. Whilst 
duloxetine leads to a 50% to 54% reduction in IEF, the TVT 
is associated with an 81% subjective cure rate at 5 years.6 
Results from a study examining patient expectations from 
treatments for incontinence indicated that 69% of women ﬁ  nd 
the option of taking regular medications for life unacceptable.43 
Additionally, the majority of women expect a complete cure of 
their incontinence, which is more likely to be achieved with a 
surgical procedure than duloxetine treatment. It does therefore 
seem logical that most women would choose to have a one-off 
minimally invasive surgical procedure with a higher success 
rate, as opposed to taking a medication which is associated 
with a signiﬁ  cant incidence of adverse effects.
The place of duloxetine may therefore be in women who 
are unﬁ  t for surgery or who do not wish to undergo surgery. 
It may also be used in women with severe incontinence who 
are awaiting surgery, or in women who have yet to complete 
their families. Despite the availability of medical and surgical 
options, it is known that many women never receive treatment 
for SUI due to various treatment barriers (either economic or 
psychosocial). Duloxetine is also not licensed for use in all 
countries, meaning that the option of medical therapy is denied 
to many women. The challenge for future research is to inves-
tigate other agents which may confer similar treatment beneﬁ  ts 
to duloxetine, with a lower incidence of side effects.
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